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Akt/mTORThe phosphoinositol 3-kinase/Akt pathway plays a critical role in oncogenesis and the dysregulation of this
pathway through loss of PTEN is a particularly common phenomenon in aggressive prostate cancers. Several
recent studies have indicated that ursolic acid (UA), a pentacyclic triterpenoid, and its derivatives inhibit the
growth of cancer cells by cell cycle arrest and the stimulation of apoptosis. In the present study, we report a
novel autophagic response of UA in PTEN-deﬁcient PC3 prostate cancer cells. As one of the major types of pro-
grammed cell death, autophagy has been observed in response to several anticancer drugs and demonstrated
to be responsible for cell death. UA-induced autophagy in PC3 cells is associated with the reduced cell viabil-
ity and the enhanced expression of LC3-II, an autophagosome marker in mammals, and monodansylcadaver-
ine incorporation into autolysosomes. Furthermore, we found that UA exhibited anti-proliferative effects
characterized by G1 phase arrest and autophagy at an early stage that precedes apoptosis. We also show
that UA-induced autophagy in PC3 cells are mediated through the Beclin-1 and Akt/mTOR pathways. Inhibi-
tion of autophagy by either 3-methyladenine or Beclin-1/Atg5 small interfering RNA enhanced UA-induced
apoptosis. Taken together, our data suggest that autophagy functions as a survival mechanism in PC3 cells
against UA-induced apoptosis and a rational for the use of autophagy inhibitors in combination with UA as
a novel modality of cancer therapy.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer is among the most commonly diagnosed male dis-
eases and a leading cause of cancer mortality in men [1]. More than
half of all men are diagnosed with cancer over the age of 70 years,
with prostate cancer constituting about 50% of the cancers in this
age group [2]. The development of prostate cancer in humans has
been viewed as a multistage process involving the onset as small la-
tent carcinoma of low histological grade to large metastatic lesion of
higher grade [3]. Because chemotherapy and radiation therapy are
largely ineffective, and metastatic diseases frequently develop even
after potentially curative surgery, there are limited treatment options
available for this disease [4–6]. In this context, novel ways of treating
prostate cancer must be developed.
Ursolic acid (UA), a pentacyclic triterpenoid, has been isolated
from many kinds of medicinal herbs and other plants such as Eriobo-
trya japonica, Rosmarinns ofﬁcinalis, Melaleuca leucadendron, Ocimum
sanctum, Eugenia jambolana, Calluna vulgaris, Malus domestica,
Vaccinium macrocarpon, and Glechoma hederaceae [7]. Several recent
studies have indicated that UA and its derivatives inhibit the growth
of cancer cells through cell cycle arrest and the stimulation of apopto-
sis [8–10]. Recently, it has been shown that UA can potentiate tumor+82 53 943 2762.
rights reserved.necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis and sensitize resistant cancer cells to TRAIL [11]. In animal
studies, UA has been shown to be chemopreventive [12] and to inhib-
it tumor invasion andmetastasis of esophageal carcinoma [13,14]. Be-
cause UA is relatively non-toxic to normal cells [7], an important
implication of these ﬁnding is that this agent might play a useful
role in the treatment of cancer. However, little is known regarding
the anti-tumor effects of UA as well as its underlying mechanisms
on prostate cancer.
Autophagy, or type II programmed cell death, is morphologically
characterized by a cell with an intact nucleus and an accumulation
of cytoplasmic double-membraned autophagic vacuoles called autop-
hagosomes[15,16]. These autophagosomes ultimately fuse with lyso-
somes to generate single-membraned autophagosomes capable of
degrading their contents [17]. Autophagy is controlled by mammalian
target of rapamycin (mTOR) downstream of phosphatidylinositol
3-kinase (PI3K)/Akt, which regulates cell growth and protein synthe-
sis in response to nutrient and growth factor availability [18]. There is
emerging evidence that autophagy plays an important role in the reg-
ulation of malignant cell survival [19].
In the present study, we report a novel autophagic response of UA
in PC3 prostate cancer cells. The UA-induced autophagy in PC3 cells is
associated with up-regulation and processing of autophagy-related
protein microtubule-associated protein 1 light chain 3 (LC3) and its
recruitment to the autophagosomes. Furthermore, we found that UA
exhibited anti-proliferative effects characterized by G1 phase arrest
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tion of UA-induced autophagy potentiates the anti-cancer effects of
UA, which provides a novel strategy to enhance therapeutic efﬁcacy.
2. Materials and methods
2.1. Materials
UA, 3-methyladenine (3-MA), acridine orange, monodansylcada-
verine (MDC) and propidium iodide (PI) were purchased from
Sigma Chemical Co. (St. Louis, MO). Antibodies were obtained from
Santa Cruz (Santa Cruz, CA) and Cell Signaling (Beverly, MA).
2.2. Cell culture
PC3 and DU145 cells were cultured in monolayers at 37 °C in a hu-
midiﬁed atmosphere of 95% air and 5% CO2 using Dulbecco's modiﬁed
Eagle's medium supplemented with 10% FBS, penicillin (50 U/ml),
and 50 μg/ml streptomycin.
2.3. Cytotoxicity
To determine cytotoxicity of UA, cells (2×104) were grown until
80% conﬂuence in 96-well plates, and cell viability after treatment
with various concentrations of UA for 1–2 days was assessed by
MTT assay. The absorbance at 540 nm with 620 nm reference was
read with an ELISA plate reader. Viability was expressed as percent-
age of control.
2.4. Detection of acidic vesicular organelles
Formation of acidic vesicular organelles (AVOs), a morphological
characteristic of autophagy, was detected by acridine orange staining
[20]. Cells were stained with 1 μg/ml acridine orange for 15 min and
samples were observed under a Zeiss Axiovert 200 inverted micro-
scope (excitation, 546 nm; emission, 575/640 nm).
2.5. Visualization of autophagic vacuoles
The autoﬂuorescent agent MDC was recently introduced as a spe-
ciﬁc autophagolysosome marker to analyze the autophagic process
[21]. PC3 cells were treated with 40 μM UA for 24 h. Autophagic vac-
uoles were labeled with MDC by incubating cells with 50 μM MDC in
PBS at 37 °C for 15 min. After incubation, cells were washed three
times with PBS and immediately analyzed by a Zeiss Axiovert 200
inverted microscope (excitation, 390 nm; emission, 460 nm).
2.6. GFP–LC3 translocation
The green ﬂuorescent protein (GFP)-fused LC3 was used to detect
autophagy as previously described by [22]. PC3 cells were transfected
with 2 μg of GFP–LC3 expression plasmid using Lipofectamine 2000.
After 24 h, transfected cells were treated with UA for 24 h, and the
distribution and ﬂuorescence of GFP–LC3 were visualized by ﬂuores-
cence microscopy.
2.7. Immunoblot analysis
Total protein extracts were separated on 10–12.5% SDS-PAGE and
transferred to the nitrocellulose membrane. The membrane was incu-
bated with the desired primary antibody, followed by a horseradish
peroxidase-labeled anti-rabbit IgG. The immune-reactive bands
were visualized by an enhanced chemiluminescence detection kit
(Amersham Pharmacia Biotech).2.8. DNA fragmentation
To determine the degradation of chromosomal DNA into
nucleosome-sized fragments, a 500 μl aliquot of the lysis buffer
(100 mM Tris–HCl, pH 8.5, EDTA, 0.2 M NaCl, 0.2% SDS, and 0.2 mg/
ml proteinase K) was added to the cell pellet (2×105 cells) and incu-
bated at 37 °C overnight. DNA was obtained by ethanol precipitation,
separated in a 0.8% agarose gel, and visualized under UV light.2.9. Flow cytometric analysis
PC3 cells were collected at 2000×g for 5 min and washed twice
with cold PBS, ﬁxed in 70% ethanol for at least 2 h at −20 °C, dec-
anted ethanol by centrifuge, and stained with 1 ml of PI staining solu-
tion (50 μg PI, 100 U RNase A, and 1.5% Triton X-100) for at least 1 h
in the dark at 4 °C. The labeled cells were analyzed by ﬂow cytometry.
Apoptosis was quantiﬁed by measuring the sub-G1 population on the
cell cycle data acquired by ﬂow cytometry.2.10. RNA interference
siRNA sequences for Beclin-1 [23], Atg5 [24], and their scrambled
controls were obtained from Invitrogen (Carlsbad, CA). Transfection
of siRNA was performed with Lipofectamine 2000 according to the
protocol provided by the manufacturer (Invitrogen).2.11. Statistical analysis
All experiments were performed at least three times. The data
were expressed as means±S.D. The difference between two mean
values was evaluated using the Student's t-test and was considered
to be statistically signiﬁcant when pb0.05.3. Results and discussion
3.1. PC3 and DU145 have distinct PTEN expression and Akt activation
The PI3K/Akt pathway is the cell survival pathway that is impor-
tant for normal cell growth and proliferation [25]. This pathway has
also been implicated in tumorigenesis [26] and is becoming an impor-
tant target for cancer therapy [27,28]. PI3K/Akt signaling is frequently
activated in various types of cancers, and hence, represents a major
cell survival pathway. Its activation has long been associated with
malignant transformation and apoptotic resistance [29,30]. The
tumor suppressor PTEN is a dual protein and phosphoinositide phos-
phatase that negatively controls the PI3K/Akt signaling pathway [31].
The loss of PTEN function is associated with a hyperactivated PI3k/Akt
pathway [28,32]. To assess the role of PTEN status in response to UA
treatment, PTEN−/− PC3 and PTEN+/+ DU145 prostate cancer
cells were ﬁrst screened by Western blot analysis to determine the
PTEN expression and phosphorylation of Akt. As shown in Fig. 1A,
PC3 cells demonstrated no PTEN expression, which correlated to
high levels of phosphorylated Akt, whereas the DU145 cells displayed
high PTEN levels, which correlated with no detectable levels of phos-
phorylated Akt. We next tested whether prostate cancer cells with
variant PTEN status responded differently to the cytotoxic effects of
UA. PC3 and DU145 cells were treated with increasing concentrations
of UA. As shown in Fig. 1B, PC3 cells were more resistant to the anti-
proliferative effects of UA. PARP cleavage, an indicative of apoptosis,
increased in DU145 cells compared to PC3 cells upon exposure to
UA (Fig. 1C). These ﬁndings are in agreement with published reports
indicating that Akt hyperactivation confers resistance to chemothera-
py [32,33].
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Fig. 1. PTEN status confers chemoresistance to UA in prostate cancer cells. (A) Twenty μg of protein lysate was separated on 10% SDS-PAGE by electrophoresis and immunoblotted
for PTEN, phosphorylated Akt, and total Akt. (B) Treatment with increasing doses of UA (10–40 μM) for 24 h showed a higher cytotoxicity in the PTEN-positive DU-145 cells when
compared with the PTEN-negative PC-3 cells. Cell viability was determined by MTT assay. Data are presented as means±S.D. of three separate experiments. *pb0.01 versus DU145
cells exposed to UA. (C) Immunoblot analysis of the apoptotic marker protein expressed in prostate cancer cells. Cells were treated with 10–40 μMUA for 24 h. The cell-free extracts
(20 μg protein) were subjected to 10% SDS-PAGE and immunoblotted with antibodies against cleaved-PARP. β-Actin was used as an internal control.
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The in vitro anticancer activity is due to the combined induction of the
apoptotic program, G1 arrest, and reduced DNA synthesis [34]. To deter-
mine whether UA would induce cell cycle arrest, we analyzed the effect
of UA on the cell cycle distribution using PI staining and ﬂow cytometry.
When PC3 cells were treated for 24 h with various concentrations of UA,UA 0
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Fig. 2. UA resulted in G1 arrest in PC3 cells. (A) DNA content analysis of PC3 cells treated
markers. PC3 cells were treated with various concentrations of UA for 24 h. Total cell extract
ing control) as indicated.the population of cells in theG1 phase increased signiﬁcantly from43.13%
to 63.35% at 40 μM of UA (Fig. 2A). Further examination of molecular
markers associatedwith G1 arrest showed remarkable changes, including
increased p21 and p27 levels and reduced cyclin D1, D3 and CDK4 levels
(Fig. 2B). The Western blot data are consistent with the G1 arrest phe-
nomenon observed in the ﬂow cytometric analysis and these results sug-
gest that UA markedly induces G1 arrest.1
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We veriﬁed that UA triggers G1 phase arrest however, it did not in-
duce apoptosis in the early stages of UA-induced cell death. Recent in-
vestigations indicate that chemo-therapeutic drugs, or any of several
other anticancer stimuli such as aromatic amine p-anilinoaniline, in-
duce autophagy but not apoptosis in various cancer cells [35]. Fur-
thermore, the cytotoxicity of many anticancer agents is mediated by
autophagy activation, which is associated with G1 arrest [34,36,37].
The process of autophagy starts with the autophagosome formation
and then progresses to autophagolysosomes through the fusion of
acidic lysosomes with autophagosomes [38]. In order to verify wheth-
er UA induced the autophagic pathway, acridine orange staining of
the live cells was employed to visualize acidic autophagolysosomes
in control and UA-treated PC3 cells. As shown in Fig. 3A, UA treatment
markedly elevated the amount of autophagolysosomes in the cells.
Furthermore, we measured the incorporation of MDC, a marker for
the acidic compartment of autolysosomes [37]. It is known that
MDC accumulates in mature autophagic vacuoles (AVs) such as
autophagolysosomes, but not in the early endosome compartment
[21]. When cells were observed with a ﬂuorescence microscope, AVs
stained by MDC appear as distinct dot-like structures distributed
within the cytoplasm or localizing in the perinuclear regions. As
shown in Fig. 3B, there was an increase in the number of MDC-
labeled vesicles at 24 h after the UA treatment. The results indicated
an induction of AV formation by UA. To obtain better insight into
the mechanism of UA-induced autophagy, we next analyzed the ef-
fects of UA on LC3-II protein, the lipidated form of mammalian
microtubule-associated protein 1 light chain LC3-I. LC3-II is produced
during autophagosome formation and the accumulation of LC3-II is
considered one of the hallmarks of autophagy [22,39]. Using Western
blot analysis with the anti-LC3 antibody, we examined theNF - 30 μM  
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Fig. 3. UA induced autophagy in PC3 cells. (A) UA-induced formation of autophagic vacuole
formation of autophagic vacuoles in PC3 cells treated in the nutrient-free condition or treate
ﬂuoresce green, whereas the acidic compartments ﬂuoresce bright red or orange-red. (B) P
mature autophagic vacuoles, such as autophagolysosomes, were observed. MDC staining of
mal number, was presented as a positive control. (C) Total cell extracts were assayed by imm
UA treated cells. PC3 cells transiently transfected with GFP–LC3 using Lipofectamine 2000 (I
24 h. Accumulation of GFP–LC3 puncta was observed in UA-treated transient transfectant.expressions of LC3-I (18 kDa) and LC3-II (16 kDa) in PC3 cells after
treatment with various concentrations of UA. As shown in Fig. 3C,
UA treatment of PC3 cells resulted in strong up-regulation of the
LC3-II protein. Induction of autophagy by UA was also demonstrated
by monitoring PC3 cells transfected with GFP–LC3 expressing vector.
Fluorescence microscopy revealed a diffuse localization of GFP–LC3 in
control cells. In contrast, treatment of cells with UA for 24 h produced
punctas of GFP–LC3 ﬂuorescence (Fig. 3D).
3.4. UA on mTOR signaling in PC3 cells
Our data indicate that UA induces both G1 cell cycle arrest and
autophagy. The common link of these two processes is that they can
be modulated by mTOR signaling. mTOR, a PI3K-related serine/threo-
nine kinase, plays a central role in regulating cell growth, prolifera-
tion, and survival, partly by regulation of translation initiation
through interactions with other proteins such as raptor (forming
mTOR complex 1, mTORC1) and rictor (forming mTOR complex 2,
mTORC2). mTORC1 is primarily activated by the PI3K/Akt pathway
[40,41]. PI3K–Akt activation is well-known to suppress autophagy in
mammalian cells [18,31,42,43]. Activated mTOR is generally believed
to be involved in the negative control of mammalian autophagy, al-
though the mTOR effectors that regulate autophagy have not been
clearly elucidated [39,44,45]. Rapamycin, an mTOR inhibitor, exerted
its antitumor effect by inducing autophagy, suggesting that it disrupts
the PI3K/Akt signaling pathway in malignant cancer cells [46]. Cer-
amide was shown to trigger autophagy by interfering with the
mTOR signaling pathway [47,48]. We examined the role of the Akt/
mTOR signaling pathway in UA-induced autophagy. UA treatment of
PC3 cells resulted in a marked reduction of phosphorylation of Akt.
UA did not cause any change in the protein levels of total Akt
(Fig. 4A). In addition, treatment of UA decreased the phosphorylationLC3-I
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Fig. 4. UA treatment impacted on the mTOR signaling pathway. (A) Immunoblot analysis of the impact of vehicle or UA treatment of PC3 cells for 24 h on the levels of indicated
proteins and phosphoproteins. (B) Inﬂuence of Akt overexpression by active Akt cDNA transfection on UA-mediated autophagy. Total cell extracts were assayed by immunoblot
analysis for expression of LC3-II in Akt cDNA-transfected cells treated with or without UA. LC3-II bands were normalized to β-actin. (C) Effect of active Akt cDNA transfection on
UA-induced LC3 translocation. PC3 cells transiently transfected with GFP–LC3 were pretreated or not with 5 mM 3-MA for 1 h and further treated with 40 μMUA for 24 h to observe
the translocation of GFP–LC3.
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S6 kinase (p70S6K) and the eukaryotic translation initiation factor
4E-binding protein 1 (4E-BP1) (Fig. 4A). Both proteins play anE
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autophagy, we transfected PC3 cells with constitutively active form
of Akt cDNA (Fig. 4B). Transfected cells expressing active Akt cDNA
were considerably more resistant to UA-induced autophagy than
cells transfected with the control cDNA. UA was notably unable to
cause autophagy, which is reﬂected by attenuated accumulation of
LC3-II, in cells transfected with active Akt cDNA, whereas UA could
maintain its autophagy effects on PC3 transfected with the control
cDNA (Fig. 4B). Similar results were also observed with UA-induced
LC3 translocation in cells transfected with active Akt cDNA (Fig. 4C).
Therefore, it can be ﬁrmly concluded that UA induces autophagy in
PC3 cells by suppression of the Akt/mTOR pathway. Based on this
data, we propose that UA leads to a consequent inhibition of Akt
and mTOR signaling, which contributes to the effects on cell cycle
progression and autophagy.
3.5. Autophagy counteracts UA-induced apoptosis
As mentioned above, we found that UA induced autophagy in
early stage of the UA-induced cell death. In agreement with the
above data, although UA-treated cells were arrested at the G1 phase,
but these cells did not undergo apoptosis at 24 h. Time-course of
cleaved PARP and LC3-II expression also showed that autophagy pro-
ceeded apoptosis (Fig. 5A). To elucidate the involvement of the
autophagic process in UA-induced apoptosis, the effects of autophagy
inhibitor were tested. The UA-induced LC3 translocation was inhib-
ited by 3-MA, a speciﬁc inhibitor of autophagy [50] (Fig. 5B), and
cell viability was markedly decreased (Fig. 5C). In addition, the effect
of 3-MA on UA-induced apoptosis was determined by analysis of sub-
diploid cells by ﬂow cytometry following staining with PI. Results
showed that 3-MA alone had little effect on sub-G1 fraction, an indi-
cator of apoptotic cell death; however, pretreatment of PC3 cells
with 3-MA signiﬁcantly increased the UA-induced sub-G1 apoptotic
population (Fig. 5D). These results suggest that autophagy is a protec-
tive mechanism in the context of PC3 cells that perhaps allowed cells+-+-Atg5 siRNA
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bodies against Beclin-1, Atg5, cleaved PARP, LC3, and β-actin as indicated.to escape from apoptosis. The 3-MA-mediated augmentation of UA-
induced apoptosis was conﬁrmed by analysis of DNA fragmentation,
cleavage of PARP, and activation of caspase 8. As can be seen in
Fig. 5E and F, both DNA fragmentation, cleavage of PARP, and activa-
tion of caspase 8 were signiﬁcantly higher in PC3 cells co-treated with
3-MA and UA compared with that observed on treatment with UA
alone. We also employed a knockdown strategy to impair autophagy
in order to further assess its impact on UA-induced cell death. To in-
vestigate the speciﬁc functional role of key autophagy proteins
Beclin-1 and Atg5 in UA-induced autophagy, we used an RNA inter-
ference approach for their speciﬁc inhibition. The silencing of Beclin
1 and Atg5 using their respective siRNA markedly induced cell
death elicited by UA treatment (Fig. 6A and B). Knockdown of either
Beclin-1 or Atg5 expression also resulted in the reduction of LC3-II
production and accumulation of cleaved PARP in UA-treated cells
(Fig. 6C and D), conﬁrming a direct impact of knockdown on the
autophagic process in the cells and consequent augmentation of apo-
ptosis. Collectively, these studies suggest that the induction of autop-
hagy provided a prosurvival role and delayed cell death during UA-
induced injury to PC3 cells. Depending on the cellular context and/
or initiating stimulus, autophagy may act as a protective mechanism
for malignant cells or exhibit opposing effects and promote genera-
tion of antineoplastic responses [51]. Autophagy has been regarded
as a tumor repression mechanism [17,34]. In contrast, recent studies
report that inhibition of the autophagy exacerbated apoptosis, indi-
cating that autophagy may be a protective response against anti-
cancer agents that contributes to tumor progression [17,52-54]. In
this aspect, the autophagic pathway is a novel therapeutic target for
cancer treatment [52,54]. Autophagy inhibition enhances the antican-
cer effect of arsenic trioxide [19], hyperthermia [19], sulforaphane
[55], and p53 or alkylating drugs [56]. These studies demonstrate
that autophagy promotes cellular survival during UA-induced prea-
poptotic lag phase, resulting in delayed apoptotic response. Induction
of autophagy during the initial period of UA insult may provide an ap-
propriate environment to maintain cellular homeostasis beforeBeclin-1 siRNA
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UA, and the viability of PC3 cells was measured by MTT analysis. Data are presented as
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0 μM UA, and total lysates were resolved by SDS-PAGE and immunoblotted with anti-
457S.W. Shin et al. / Biochimica et Biophysica Acta 1823 (2012) 451–457reaching the threshold for UA-induced apoptosis. Thus, at the initial
stages of UA injury, autophagy may function efﬁciently in eliminating
unwanted or damaged organelles and other cytoplasmic macromole-
cules to establish cellular homeostasis.
4. Conclusions
This study shows that UA produces in vitro growth inhibition, G1
cell cycle arrest, and autophagy in the early stage of UA-induced cell
death. Autophagy offers protection from the anti-cancer activity of
UA in PC3 cells, and a combination of UA with autophagy inhibitors
strengthens the therapeutic efﬁcacy based on proapoptotic strategies.
Collectively, this study indicates that a combination of UA with autop-
hagy inhibitors might be essential in overcoming prostate cancer cell
resistance. Furthermore, the approach may be an effective therapeu-
tic strategy, in general, to sensitize therapy resistant cancer cells.
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